Evidence map›Paper›PMID 35008521›Full record

ArticleInternational journal of molecular sciences2021

Specific Inhibition of VanZ-Mediated Resistance to Lipoglycopeptide Antibiotics.

Vishma Pratap Sur, Aninda Mazumdar, Vladimir Vimberg, Tommaso Stefani, Ladislav Androvic, Lucie Kracikova, Richard Laga, Zdenek Kamenik, Katerina Komrskova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Journal of microbiology and biotechnology · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Functional Analysis of Hypothetical Proteins ofBioinformatics and biology insights · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Vishma Pratap SurLaboratory of Reproductive Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic.ORCID 0000-0002-1175-7194
Aninda MazumdarLaboratory for Biology of Secondary Metabolism, Institute of Microbiology of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic.ORCID 0000-0002-4985-7115
Vladimir VimbergLaboratory for Biology of Secondary Metabolism, Institute of Microbiology of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic.
Tommaso StefaniLaboratory for Biology of Secondary Metabolism, Institute of Microbiology of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic.ORCID 0000-0002-4414-6787
Ladislav AndrovicDepartment of Polymer and Colloid Immunotherapeutics, Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovskeho namesti 2, 162 06 Prague, Czech Republic.
Lucie KracikovaDepartment of Polymer and Colloid Immunotherapeutics, Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovskeho namesti 2, 162 06 Prague, Czech Republic.
Richard LagaDepartment of Polymer and Colloid Immunotherapeutics, Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovskeho namesti 2, 162 06 Prague, Czech Republic.
Zdenek KamenikLaboratory for Biology of Secondary Metabolism, Institute of Microbiology of the Czech Academy of Sciences, Videnska 1083, 142 20 Prague, Czech Republic.
Katerina KomrskovaLaboratory of Reproductive Biology, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, 252 50 Vestec, Czech Republic.ORCID 0000-0002-6837-2148
Czech Academy of Sciences · CZCzech Academy of Sciences, Institute of Macromolecular Chemistry · CZCharles University · CZCzech Academy of Sciences, Institute of Biotechnology · CZ

Funding

BIOCEV CZ.1.05/1.1.00/02.0109Czech Academy of Sciences LQ200202002Czech Science Foundation 19-08176SCzech Science Foundation 20-09811YInstitute of Biotechnology RVO 86652036Ministry of Health of the Czech Republic NU20-03-00309
6 · The paper itself

Abstract

Teicoplanin is a natural lipoglycopeptide antibiotic with a similar activity spectrum as vancomycin; however, it has with the added benefit to the patient of low cytotoxicity. Both teicoplanin and vancomycin antibiotics are actively used in medical practice in the prophylaxis and treatment of severe life-threatening infections caused by gram-positive bacteria, including methicillin-resistant

Indexed as

Anti-Bacterial AgentsBacterial ProteinsDrug Resistance, BacterialGram-Positive BacteriaGram-Positive Bacterial InfectionsHumansLipoglycopeptidesMicrobial Sensitivity TestsMolecular Docking SimulationTeicoplaninVancomycinAnti-Bacterial AgentsBacterial ProteinsLipoglycopeptidesTeicoplaninVancomycinantibiotic resistancebenzimidazoledockingEnterococcus faeciumligandslipoglycopeptide antibioticMD simulationStaphylococcus aureusteicoplanin VanZ

Identifiers

PMID35008521
PMCPMC8744867
OpenAlexW4200486799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.